Oct 7, 2026 09:59AM

Oct 2, 2026 06:03AM

Oct 2, 2026 06:00AM

Sep 29, 2026 08:05AM

Sep 29, 2026 08:03AM

Sep 25, 2026 11:32AM

Sep 25, 2026 07:30AM Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) st

Sep 25, 2026 07:00AM

Sep 23, 2026 09:47AM

Sep 23, 2026 09:46AM

Sep 21, 2026 08:00AM

Sep 21, 2026 08:00AM

Sep 15, 2026 06:04AM

Sep 14, 2026 11:00PM RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026

Sep 14, 2026 04:30AM

Sep 13, 2026 09:45PM

Sep 10, 2026 07:46AM

Sep 10, 2026 07:45AM

Sep 8, 2026 08:02AM

Sep 8, 2026 08:00AM

Aug 26, 2026 02:00PM FDA: issues early alert on Abiomed heart pump controller purge cassette issue

Aug 24, 2026 07:13PM

Aug 24, 2026 07:12PM

Aug 5, 2026 10:26AM

Aug 5, 2026 10:25AM

Aug 4, 2026 09:05AM

Aug 3, 2026 02:37PM

Jul 30, 2026 08:30AM FDA grants priority review to J&J cancer drug for head and neck tumors

Jul 30, 2026 08:30AM

Jul 23, 2026 08:31AM

Jul 23, 2026 08:30AM

Jul 22, 2026 07:01AM

Jul 22, 2026 07:00AM

Jul 15, 2026 06:20AM

Jul 8, 2026 07:45AM FDA clears Johnson & Johnson dual-energy cardiac ablation catheter

Jul 8, 2026 07:45AM

Jun 30, 2026 09:00AM

Jun 26, 2026 12:35PM

Jun 26, 2026 12:35PM

Jun 14, 2026 02:01PM

Jun 13, 2026 06:33AM

Jun 11, 2026 07:45AM Johnson & Johnson expands US availability of TECNIS PureSee IOL

Jun 11, 2026 07:45AM

Jun 11, 2026 07:43AM

Jun 11, 2026 02:03AM

Jun 11, 2026 02:03AM

Jun 3, 2026 03:14AM

Jun 3, 2026 12:04AM

Jun 3, 2026 12:04AM Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Jun 3, 2026 12:03AM

333,381 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All